Acyclovir To Prevent Cytomegalovirus Infection after Renal Transplantation

Letters1 July 1991Acyclovir To Prevent Cytomegalovirus Infection after Renal TransplantationTony Wong, MD, Olivier Toupance, MD, Jacques Chanard, MDTony Wong, MDSearch for more papers by this author, Olivier Toupance, MDSearch for more papers by this author, Jacques Chanard, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-115-1-68_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: The recent article by Plotkin and colleagues (1) confirms the role of pretransplant immunity in the reduction of cytomegalovirus disease severity in renal transplant recipients at high risk for primary disease. It is noteworthy that the Towne live virus vaccine did not induce latency or increase the incidence of neoplasm. In the accompanying editorial, Balfour (2) commented on the different options for preventing cytomegalovirus disease. He underlined his enthusiasm for the use of high-dose acyclovir in "all patients."On the basis of the results of a 1989 study by Balfour and colleagues, we conducted an open-label trial...References1. Plotkin S, Starr S, and Friedman H. Effects of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med. 1991;114:525-31. LinkGoogle Scholar2. Balfour H. Options for prevention of cytomegalovirus disease. Ann Intern Med. 1991;114:598-9. LinkGoogle Scholar3. Balfour H, Chace B, and Stapleton J. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989:320:1381-7. CrossrefMedlineGoogle Scholar4. Bowden R, Sayers M, and Flournoy N. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314:1006-10. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Tony Wong, MD; Olivier Toupance, MD; Jacques Chanard, MDAffiliations: Centre Hospitalier Universitairre de Reims Reims, France 51092 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byFailure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplantsAntimicrobial strategies in the care of organ transplant recipientsSymptomatic Cytomegalovirus Infection in Renal Transplant Recipients Given Either Minnesota Antilymphoblast Globulin (MALG) or OKT3 for Rejection ProphylaxisStrategies for the treatment and prevention of cytomegalovirus infections 1 July 1991Volume 115, Issue 1Page: 68-68KeywordsCytomegalovirus infectionImmunityRenal diseasesRenal transplantationVaccines ePublished: 1 December 2008 Issue Published: 1 July 1991 PDF downloadLoading ...